Optical imaging, photodynamic therapy and optically triggered combination treatments

Cancer Journal (United States)

Volumn 21, Issue 3, 2015, Pages 194-205

  Mallidi, Srivalleesha ^a   Spring, Bryan Q ^a   Chang, Sung ^a   Vakoc, Benjamin ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activatable probes; dosimetry; fluorescence imaging; hyperspectral imaging and photoacoustic imaging; image guided therapy; molecular imaging; optical coherence tomography; optical imaging; photodynamic therapy; photosensitizer

Indexed keywords

PHOTOSENSITIZING AGENT; PROTOPORPHYRIN; VERTEPORFIN;

BASAL CELL CARCINOMA; CANCER THERAPY; CONFOCAL MICROSCOPY; FLUORESCENCE IMAGING; HUMAN; NANOTECHNOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTOACOUSTICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME; COMPUTER ASSISTED SURGERY; DIAGNOSTIC IMAGING; IMAGE GUIDED RADIOTHERAPY; MOLECULAR IMAGING; NEOPLASMS; PHOTOCHEMOTHERAPY; PROCEDURES; RADIOGRAPHY;

HUMANS; MOLECULAR IMAGING; NEOPLASMS; PHOTOCHEMOTHERAPY; RADIOGRAPHY; RADIOTHERAPY, IMAGE-GUIDED; SURGERY, COMPUTER-ASSISTED;

EID: 84930585912     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000117     Document Type: Review

References (100)

1. Siegel RL, MillerKD, Jemal A. Cancer statistics, 2015. CACancer J Clin. 2015;65:5-29.
2. Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110: 2795-2838.
3. Verma S, Watt GM, Mai Z, et al. Strategies for enhanced photodynamic therapy effects. Photochem Photobiol. 2007;83:996-1005.
4. Spring BQ, Abu-Yousif AO, Palanisami A, et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci USA. 2014;111:E933-E942.
5. Huang H-C, Hasan T. The "nano" world in photodynamic therapy. Austin J Biomed Eng. 2014;2:1-4.
6. Eljamel MS, Goodman C, Moseley H. ALA and Photofrin fluorescenceguided resection and repetitive PDT in glioblastoma multiforme: a single centre phase III randomised controlled trial. Lasers Med Sci. 2008;23: 361-367.
7. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, et al. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol. 2012;19:6227-6231.
8. Wilson BC, PattersonMS, Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci. 1997;12:182-199.
9. Mallidi S, Anbil S, Lee S, et al. Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. J Biomed Opt. 2014;19:028001.
10. Zhou X, Pogue BW, Chen B, et al. Pretreatment photosensitizer dosimetry reduces variation in tumor response. Radiat Oncol Biol. 2006;64: 1211-1220.
11. Mallidi S, Watanabe K, Timerman D, et al. Prediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging. Theranostics. 2015;5:289-301.
12. Vakoc BJ, Fukumura D, Jain RK, et al. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat Rev Cancer. 2012;12:363-368.
13. Vakoc BJ, Lanning RM, Tyrrell JA, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009;15:1219-1223.
14. Jang I-K, Bouma BE, Kang D-H, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol. 2002;39:604-609.
15. Evans CL, Rizvi I, Celli J, et al. Visualizing photodynamic therapy response with time-lapse OCT in an in vitro model of metastatic ovarian cancer. SPIE. 2010:75510J.
16. Aalders MCG, Triesscheijn M, Ruevekamp M, et al. Doppler optical coherence tomography tomonitor the effect of photodynamic therapy on tissue morphology and perfusion. J Biomed Opt. 2006;11:044011.
17. Themstrup L, Banzhaf CA, Mogensen M, et al. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions. Photodiagnosis Photodyn Ther. 2014;11:7-12.
18. Jung Y, Nichols AJ, Klein OJ, et al. Label-free, longitudinal visualization of PDT response in vitro with optical coherence tomography. Isr J Chem. 2012;52:728-744.
19. Evans CL, Rizvi I, Hasan T, et al. In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging. Opt Express. 2009;17:8892-8906.
20. Hamdoon Z, Jerjes W, Upile T, et al. Optical coherence tomographyguided photodynamic therapy for skin cancer: case study. Photodiagnosis Photodyn Ther. 2011;8:49-52.
21. McLaughlin RA, Quirk BC, Curatolo A, et al. Imaging of breast cancer with optical coherence tomography needle probes: feasibility and initial results. IEEE J. 2012;18:1184-1191.
22. Yun SH, Tearney GJ, Vakoc BJ, et al. Comprehensive volumetric optical microscopy in vivo. Nat Med. 2006;12:1429-1433.
23. Khurana M, Moriyama EH, Mariampillai A, et al. Intravital highresolution optical imaging of individual vessel response to photodynamic treatment. J Biomed Opt. 2008;13:040502.
24. Standish BA, Yang VXD, Munce NR, et al. Doppler optical coherence tomography monitoring of microvascular tissue response during photodynamic therapy in an animal model of Barrett's esophagus. Gastrointest Endosc. 2007;66:326-333.
25. Xiang L, Xing D, Gu H, et al. Real-time optoacoustic monitoring of vascular damage during photodynamic therapy treatment of tumor. J Biomed Opt. 2007;12:014001-1.
26. Smith TK, Choi B, Ramirez San Juan JC, et al.Microvascular blood flow dynamics associated with photodynamic therapy, pulsed dye laser irradiation and combined regimens. Lasers Surg Med. 2006;38:532-539.
27. Chen B, Pogue BW, Hoopes PJ, et al. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Radiat Oncol Biol. 2005;61:1216-1226.
28. Chen B, Pogue BW, Hoopes PJ. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;16:279-306.
29. Woodhams JH, MacRobert AJ, Bown SG. The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry. Photochem Photobiol Sci. 2007;6:1246-1256.
30. Foster TH, Hartley DF, Nichols MG, et al. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res. 1993;53:1249-1254.
31. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med. 2006;38:489-493.
32. Yu G, Durduran T, Zhou C, et al. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res. 2005;11:3543-3552.
33. Sunar U, Rohrbach D, Rigual N, et al.Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report. Opt Express. 2010;18:14969.
34. Mallidi S, Luke GP, Emelianov SY. Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance. Trends Biotechnol. 2011;29: 213-221.
35. XuM, Wang LV. Photoacoustic imaging in biomedicine. Rev Sci Instrum. 2006;77:041101.
36. Lüdicke F, Gabrecht T, Lange N, et al. Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study. Br J Cancer. 2003; 88:1780-1784.
37. Yelin D, Rizvi I, White WM, et al. Three-dimensional miniature endoscopy. Nature. 2006;443:765.
38. Hsiung P-L, Hardy J, Friedland S, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med. 2008;14:454-458.
39. Williams RM, Flesken-Nikitin A, Ellenson LH, et al. Strategies for highresolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol. 2010;3:181-194.
40. Pierce MC, Guan Y, Quinn MK, et al. A pilot study of low-cost, highresolution microendoscopy as a tool for identifying women with cervical precancer. Cancer Prev Res. 2012;5:1273-1279.
41. Ford TN, Lim D, Mertz J. Fast optically sectioned fluorescence HiLo endomicroscopy. J Biomed Opt. 2012;17:021105-021157.
42. Zavaleta CL, Garai E, Liu JTC, et al. A Raman-based endoscopic strategy for multiplexed molecular imaging. Proc Natl Acad Sci USA. 2013;110: E2288-E2297.
43. Mitra S, Goren EM, Frelinger JG, et al. Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol. 2003;78:615-622.
44. Gomer CJ, Ryter SW, Ferrario A, et al. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 1996;56:2355-2360.
45. Ferrario A, Rucker N, Wong S, et al. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 2007;67:4989-4995.
46. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and antitumour immunity. Nat Rev Cancer. 2006;6:535-545.
47. Chang SK, Rizvi I, Solban N, et al. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res. 2008;14:4146-4153.
48. Ferrario A, Tiehl von KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066-4069.
49. Solban N, Selbo PK, Pål SK, et al. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res. 2006;66:5633-5640.
50. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, et al. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis. 2010;13:281-292.
51. Weiss A, van Beijnum UR, Bonvin D, et al. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell MolMed. 2014;18:480-491.
52. Nowak-Sliwinska P, Weiss A, Beijnum JRV, et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med. 2012;16:1553-1562.
53. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
54. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J NuclMed Soc Nucl Med. 2007;48:1313-1319.
55. Zimmermann T, Rietdorf J, Pepperkok R. Spectral imaging and its applications in live cell microscopy. FEBS Lett. 2003;546:87-92.
56. Mansfield JR, Gossage KW, Hoyt CC, et al. Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. J Biomed Opt. 2005;10:41207.
57. Kosharskyy B, Solban N, Chang SK, et al. AMechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res. 2006;66:10953-10958.
58. Eljamel S. Photodynamic applications in brain tumors: a comprehensive review of the literature. Photodiagnosis Photodyn Ther. 2010;7: 76-85.
59. Zimmermann A, Ritsch-Marte M, Kostron H. mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol. 2001;74:611-616.
60. Savellano MD, Hasan T. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin Cancer Res. 2005;11: 1658-1668.
61. Abu-Yousif AO, Moor ACE, Zheng X, et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 2012;321:120-127.
62. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection ofmalignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392-401.
63. van Dam GM, Themelis G, Crane LMA, et al. Intraoperative tumorspecific fluorescence imaging in ovarian cancer by folate receptor-targeting: first in-human results. Nat Med. 2011;17:1315-1319.
64. Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation-a new cutting edge. Nat Rev Cancer. 2013;13:653-662.
65. Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31.
66. Soussan M, Guetz Des G, Barrau V, et al. Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. Eur Radiol. 2012;22: 1479-1487.
67. Lovell JF, Liu TWB, Chen J, et al. Activatable photosensitizers for imaging and therapy. Chem Rev. 2010;110:2839-2857.
68. Mew D, Wat CK, Towers GH, et al. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol. 1983;130:1473-1477.
69. Oseroff AR, Ohuoha D, Hasan T, et al. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci USA. 1986;83: 8744-8748.
70. Goff BA, Bamberg M, Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 1991;51:4762-4767.
71. Goff BA, Hermanto U, Rumbaugh J, et al. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer. 1994;70:474-480.
72. van Dongen GAMS, Visser GWM, Vrouenraets MB. Photosensitizerantibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev. 2004;56:31-52.
73. Molpus KL, Hamblin MR, Rizvi I, et al. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol. 2000;76:397-404.
74. Mitsunaga M, Ogawa M, Kosaka N, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17:1685-1691.
75. Weissleder R, Tung C-H, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375-378.
76. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence andMRimaging of proteases. Proc Natl Acad Sci USA. 2010;107:4311-4316.
77. Urano Y, Asanuma D, Hama Y, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med. 2009; 15:104-109.
78. Ogawa M, Regino CAS, Choyke P, et al. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther. 2009;8:232-239.
79. Lee H, Akers W, Bhushan K, et al. Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors. Bioconjugate Chem. 2011;22:777-784.
80. Zheng G, Chen J, StefflovaK, et al. Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci USA. 2007;104: 8989-8994.
81. Spring BQ, Palanisami A, Hasan T.Microscale receiver operating characteristic analysis of micrometastasis recognition using activatable fluorescent probes indicates leukocyte imaging as a critical factor to enhance accuracy. J Biomed Opt. 2014;19:066006.
82. Hahn SM, Fraker DL, Mick R, et al.Aphase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006;12:2517-2525.
83. Cengel KA, Glatstein E, Hahn SM. Intraperitoneal photodynamic therapy. Cancer Treat Res. 2007;134:493-514.
84. Roberts D, Schick J, Conway S, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 2005;92:1149-1158.
85. Meirelles K, Benedict LA, Dombkowski D, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA. 2012;109: 2358-2363.
86. Rai P, Mallidi S, Zheng X, et al. Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev. 2010;62: 1094-1124.
87. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60:1627-1637.
88. Bechet D, Couleaud P, Frochot C, et al. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008;26: 612-621.
89. Ho CJH, Balasundaram G, DriessenW, et al. Multifunctional photosensitizerbased contrast agents for photoacoustic imaging. Sci Rep. 2014;4:5342.
90. Mallidi S, Huang H-C, Liu J, et al. Towards image-guided photodynamic therapy of glioblastoma. Proc SPIE. 2013:85681C.
91. Yan X, Hu H, Lin J, et al. Optical and photoacoustic dual-modality imaging guided synergistic photodynamic/photothermal therapies. In: Nanoscale. 2015;7:2520-2526.
92. Wang X, Liu K, Yang G, et al. Near-infrared light triggered photodynamic therapy in combination with gene therapy using upconversion nanoparticles for effective cancer cell killing. Nanoscale. 2014;6:9198-9205.
93. Idris NM, Gnanasammandhan MK, Zhang J, et al. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med. 2012;18:1580-1585.
94. FanW, Shen B, BuW, et al. A smart upconversion-based mesoporous silica nanotheranostic system for synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging. Biomaterials. 2014;35: 8992-9002.
95. Spring B, Mai Z, Rai P, et al. Theranostic nanocells for simultaneous imaging and photodynamic therapy of pancreatic cancer. Proc SPIE. 2010: 755104-755111.
96. Zheng LZ, Rai P, Spring B, et al. Combination therapy targeting EGFR/MET crosstalk using nanotechnology improves photodynamic therapy treatment of pancreatic cancer. Mol Cancer Ther. 2009;8(12 suppl):A127.
97. Lovell J, Jin CS, Huynh EE, et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater. 2011;10:324-332.
98. Carter KA, Shao S, Hoopes MI, et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat Commun. 2014;5:3546.
99. Mallidi S, Kim S, Karpiouk A, et al. Visualization of molecular composition and functionality of cancer cells using nanoparticle-augmented ultrasound-guided photoacoustics. Photoacoustics. 2015;3:26-34.
100. Yoon T-J, Cho Y-S. Recent advances in photoacoustic endoscopy. World J Gastrointest Endosc. 2013;5:534-539.